全文获取类型
收费全文 | 308篇 |
免费 | 22篇 |
国内免费 | 8篇 |
专业分类
妇产科学 | 1篇 |
基础医学 | 10篇 |
口腔科学 | 2篇 |
临床医学 | 23篇 |
内科学 | 129篇 |
皮肤病学 | 1篇 |
神经病学 | 47篇 |
特种医学 | 62篇 |
外科学 | 27篇 |
综合类 | 22篇 |
预防医学 | 2篇 |
眼科学 | 3篇 |
药学 | 3篇 |
中国医学 | 3篇 |
肿瘤学 | 3篇 |
出版年
2023年 | 5篇 |
2022年 | 14篇 |
2021年 | 24篇 |
2020年 | 25篇 |
2019年 | 22篇 |
2018年 | 24篇 |
2017年 | 12篇 |
2016年 | 3篇 |
2015年 | 16篇 |
2014年 | 23篇 |
2013年 | 21篇 |
2012年 | 13篇 |
2011年 | 17篇 |
2010年 | 9篇 |
2009年 | 12篇 |
2008年 | 6篇 |
2007年 | 7篇 |
2006年 | 17篇 |
2005年 | 7篇 |
2004年 | 11篇 |
2003年 | 8篇 |
2002年 | 6篇 |
2001年 | 4篇 |
2000年 | 1篇 |
1999年 | 5篇 |
1998年 | 2篇 |
1997年 | 4篇 |
1996年 | 4篇 |
1995年 | 2篇 |
1994年 | 3篇 |
1993年 | 2篇 |
1992年 | 3篇 |
1991年 | 1篇 |
1990年 | 1篇 |
1988年 | 2篇 |
1980年 | 1篇 |
1976年 | 1篇 |
排序方式: 共有338条查询结果,搜索用时 15 毫秒
1.
2.
肾癌伴下腔静脉癌栓的诊断及治疗(附11例报告) 总被引:1,自引:0,他引:1
报告11例肾细胞癌伴下腔静脉癌栓患者,男9例,女2例;右侧8例,左侧3例。临床症状:血尿9例,腹部肿物2例,仅1例出现下肢水肿、腹壁浅静脉扩张。全部病人均经CT扫描或CT和MRI检查明确诊断。10例经上腹正中或胸腹联合切口取出癌栓连同患肾一并切除。5例术前无其它部位转移者术后平均存活5年2个月,1例术后2个月死亡,2例术前肾蒂淋巴结及肾周脂肪侵犯者中1例存活2年5个月死于非肿瘤疾病,1例目前已存活3年1个月尚在,2例失访。本组腔静脉癌栓发生率占同期肾癌病人的2.7%。本组CT与MRI相结合应用诊断符合率为980%。 相似文献
3.
目的研究以碘油为主组合不同栓塞剂型治疗子宫肌瘤的疗效。方法36例子宫肌瘤患者,随机分为3组,采用与碘油不同栓塞剂组合,行双侧子宫动脉栓塞(UAE)治疗。Ⅰ组碘油 无水乙醇;Ⅱ组碘油 平阳霉素;Ⅲ组碘油 平阳霉素 无水乙醇 明胶海绵粒。术后随访观察月经恢复情况、瘤体大小、有无并发症发生等。结果Ⅰ、Ⅱ、Ⅲ3组UAE治疗后,子宫肌瘤缩小>50%分别为3、4、8例,Ⅰ、Ⅱ组间无显著性差异(P>0.05);Ⅰ、Ⅱ组与Ⅲ3组之间有显著性差异(P<0.05);Ⅰ、Ⅱ、Ⅲ3组间并发症发生率无统计学差异(P>0.05)。结论碘油与无水乙醇、平阳霉素、明胶海绵粒联合栓塞子宫肌瘤其疗效优于其它组合剂型。 相似文献
4.
目的 比较不同栓塞材料的门静脉栓塞术(PVE)与联合肝脏分隔和门静脉结扎的二步肝切除术(ALPPS)对剩余肝体积(FLR)增长速率的影响,比较各组FLR的增长速率,二期手术切除率、术中数据和术后并发症。方法 采用单中心、前瞻性、非随机对照的对比研究。2014年11月至2019年12月,海军军医大学第三附属医院共126例因FLR不足导致无法切除的肝细胞癌(HCC)或肝内胆管癌(ICC)病人,将其分为4组:ALPPS组及分别采用氰基丙烯酸正丁酯(NBCA)、微球、明胶海绵作为栓塞材料的PVE组。主要终点为FLR增长速率和二期手术切除率。结果 各组的手术切除例数及二期手术切除率分别为:ALPPS组38例(99.4%),NBCA组32例(76.2%),明胶海绵组20例(60.6%),微球组10例(83.3%)。ALPPS组、NBCA组、微球组的FLR增长速率分别为15.1 mL/d,10.0 mL/d和 8.5 mL/d,均高于明胶海绵组(3.7 mL/d)。结论 采用NBCA及微球作为栓塞材料的PVE导致FLR增长速率低于ALPPS,两种栓塞材料的PVE二期手术切除率相当。使用NBCA作为栓塞材料的PVE其FLR增长速率高于微球,且这两种栓塞材料的栓塞效果均优于明胶海绵。 相似文献
5.
6.
7.
Yukihiro Yokoyama Masato Nagino Hideki Nishio Tomoki Ebata Tsuyoshi Igami Yuji Nimura 《Journal of hepato-biliary-pancreatic sciences》2007,14(5):447-454
The clinical application of portal vein embolization (PVE) has contributed to improving the postoperative outcome of hilar cholangiocarcinoma. The enlarged nonembolized lobe after PVE protects the patient from postoperative hepatic failure, due to the increased functional reserve, and shortens the hospital stay. Although numerous reports have shown beneficial effects of PVE on postoperative outcome after extended hepatectomy, no randomized controlled study has been performed so far. It is urgent to establish a “gold standard” of PVE, because the indications, approach to the portal vein, types of embolic materials, and methods used to evaluate the function of the future liver remnant are variable among institutions. The indications and procedures of PVE for hilar cholangiocarcinoma may be different from those for hepatocellular carcinoma or colorectal metastasis, because, in many patients with hilar cholangiocarcinoma, biliary cancer is associated with biliary obstruction and cholangitis. This review article summarizes the contribution of PVE to the outcome of postoperative management in patients with hilar cholangiocarcinoma needing extended hepatectomy. We also describe our PVE procedure, which has been established from our experience of more than 240 cases of biliary cancer. Furthermore, the drawbacks of PVE, which may reduce the pool of candidates for surgery, are also discussed. 相似文献
8.
《JACC: Cardiovascular Interventions》2020,13(18):2149-2155
ObjectivesThe objective of this study was to evaluate in-hospital outcomes with use of the Sentinel cerebral protection system (CPS) in transcatheter aortic valve replacement (TAVR).BackgroundThe role of the Sentinel CPS in preventing clinical ischemic stroke has been controversial.MethodsThe Nationwide Inpatient Sample database from the last three quarters of 2017, after the approval of the Sentinel CPS device, was queried to identify hospitalizations for TAVR. A 1:2 propensity score–matched analysis to compare in-hospital outcomes with versus without use of the CPS. The primary outcome was the occurrence of ischemic strokes.ResultsA total of 36,220 weighted discharges of patients who underwent TAVR (525 with the CPS and 35,695 without) were identified. The overall percentages of ischemic and hemorrhagic strokes were 2.4% and 0.2%, respectively. After propensity score matching (525 CPS, 1,050 no CPS), the risk for ischemic stroke was lower with use of the CPS (1 % vs. 3.8%, odd ratio [OR]: 0.243 (95% confidence interval: 0.095 to 0.619); p = 0.003). The cost of the index hospitalization was higher with use of the CPS ($47,783 vs. $44,578; p = 0.002). In multivariate regression analysis, use of the CPS was independently associated with a lower risk for ischemic stroke (OR: 0.380; 95% confidence interval: 0.157 to 0.992; p = 0.032).ConclusionsUse of the Sentinel CPS in patients undergoing TAVR is associated with a lower incidence of ischemic stroke and in-hospital mortality, without an increased risk for procedural complications but with an increased cost of the index hospitalization. 相似文献
9.
10.
Embolic protection device use and its association with procedural safety and long‐term outcomes following saphenous vein graft intervention: An analysis from the British Columbia Cardiac registry
下载免费PDF全文
![点击此处可从《Catheterization and cardiovascular interventions》网站下载免费的PDF全文](/ch/ext_images/free.gif)
M. Bilal Iqbal MD PhD Imad J. Nadra MD Lillian Ding MSC Anthony Fung MD Eve Aymong MD Albert W. Chan MD Steven Hodge MD Anthony Della Siega MD Simon D. Robinson MD 《Catheterization and cardiovascular interventions》2016,88(1):73-83
- Coronary stents are commonly deployed using high pressure. However, the duration time of balloon inflation during deployment is still to be determined.
- Vallurupalli and coworkers, in this issue of CCI, show that the stent system takes an average of 33 sec to “accommodate” its pressure during in vitro deployment. In patients, the mean stent inflation time to achieve pressure stability was 104 seconds, ranging from 30 to 380 sec.
- These results challenge a rapid inflation/deflation approach for stent deployment. It is suggested that the duration of the inflation might be individualized, in a case‐by‐case approach.
- However, the findings must be interpreted with caution, as they cannot be directly extrapolated to more diverse clinical, angiographic, and interventional scenarios.